Abstract: This study aimed to investigate the utilization of antiepileptic drugs (AEDs) in children and adolescents with epilepsy and other diagnoses in a nationwide population between 2007 and 2014. Data on dispensed prescriptions of AEDs were collected from the Swedish Prescribed Drug Register and linked to diagnosis data from the National Patient Register covering all in-and outpatient consultations from Swedish hospitals. Children aged 0-17 years who had received at least one prescription for AEDs were selected. We calculated proportions of patients stratified by indication, sex and type of AED. A total of 18,131 patients (mean age 9.5 years, 50% boys) were initiated on AED treatment between January 2007 and December 2014. Epilepsy was the most frequent diagnosis (46%) recorded within the year prior to the first AED dispensing. Psychiatric and pain diagnoses were more common in girls (sex distribution 70/30 and 59/41, respectively). In epilepsy, the most frequently initiated AED was valproic acid in boys and lamotrigine in girls. Lamotrigine was the most frequently initiated drug in psychiatry, in both boys and girls. This nationwide study provides new knowledge on AED use in children and adolescents. The use of AEDs during the study period was mainly restricted to epilepsy, and the individual AEDs used seems to be in accordance with approved indications. However, the use of AED on non-epilepsy diagnoses, especially pain disorders, raises concerns.
Antiepileptic drugs (AEDs), originally developed to treat patients with epilepsy, are today also used on various non-epilepsy indications, both in neurology and in psychiatry [1] . Several AEDs have been approved for non-epileptic disorders in adults in Europe: valproic acid and lamotrigine as mood stabilizers in bipolar disorder; pregabalin for generalized anxiety disorder; pregabalin, gabapentin and carbamazepine for neuropathic pain; and topiramate as migraine prophylaxis [2] . Also, other conditions have been under investigation to expand the use of AEDs [1] . The prevalence of some of these conditions has similar sex distribution, while others show large sex differences. Affective disorders and generalized anxiety disorder are more prevalent in women and adolescent girls [3, 4] . Women are also more likely than men to experience neuropathic pain syndromes [5] . Many of the neuropathic pain syndromes for which AEDs have been studied are uncommon in children and adolescents, although some forms of neuropathic pain do exist [6] . Migraine predominantly affects women, but the gender ratio of migraine prevalence varies over life-time. More boys than girls develop migraine in younger ages, while girls are more affected after puberty [7] .
The indication pattern for AEDs differs between adults and children. The indication for AED use in children is often only epilepsy, while in adults, other indications than epilepsy are more common [8, 9] . The use of AEDs on different indications in adults has been assessed in epidemiological studies worldwide [8] [9] [10] [11] [12] [13] , but there are few studies in children and adolescents [14] [15] [16] [17] [18] . Moreover, analyses of sex differences in AED use in this patient group are few [9, 13] and lacking in Sweden. AED utilization in Sweden has previously been described for patients with epilepsy only [19] . Given the different indications and symptoms that AEDs can be prescribed for, it is of interest to investigate which indications AED is used for and assess to what extent there are sex differences in prescribing. This study aimed to investigate the initiation of AEDs related to indication in boys and girls in Sweden between 2007 and 2014.
Material and Methods
Data sources. This nationwide observational cross-sectional study is based on data from Swedish national health and population registers through anonymized record linkage based on the personal identification number [20] . Exposure data were retrieved from The Swedish Prescribed Drug Register, containing patient-level data on dispensed drugs for the entire Swedish population from 1 July 2005 onwards [21] . Classification of drugs is based on the Anatomical Therapeutic Chemical (ATC) classification codes. Information collected included patient's sex and age, dispensed drug and quantity, dates of prescribing and dispensing. Information on birth country was obtained from Statistics Sweden [22] Diseases (ICD-10) and have been available since 1997. However, the NPR does not cover diagnoses and procedures in primary care.
Study population. All children and adolescents between 0 and 17 years who were dispensed a first prescription of an AED (ATCcode N03) from 1 January 2007 until 31 December 2014 were selected from the Swedish Prescribed Drug Register. A washout period of 365 days with no claims of the same substance was applied to identify newly initiated patients on each specific drug. All AEDs available in Sweden were included, regardless of restrictions to age and approved indication. Data from the Swedish Prescribed Drug Register were linked to the NPR to extract history of diagnoses prior to the first dispensing date of an AED.
Analyses. The specific indication for which the AED was prescribed cannot be retrieved from the register data. Therefore, we classified possible indications based on International Classification of Diseases (ICD-10) codes for the officially approved indications for AEDs in Sweden (table 1 and Table S1 ). Indications in the study population were identified by analysing history of diagnoses at a time window of 12 months prior to dispensing date. This time window was considered sufficiently wide to include at least one healthcare consultation. Also, a prescription in Sweden is valid for 12 months after prescription date.
To investigate AED prescribing associated with indication, an indication hierarchy approach was used, inspired by an indication hierarchy exploring indications for statin prescribing [24] . The indication hierarchy included in hierarchical order: (i) epilepsy; (ii) unspecified convulsions; (iii) psychiatric disorder; (iv) pain disorder; (v) migraine; together with an (vi) 'other group' without any of the mentioned indications recorded (table 1). All cohort members were assigned to the indication for potential AED prescribing with the highest rank (i.e. if a patient had G40.2, R25.9 and G43 registered within 12 months prior to dispensing date, the AED indication was classified as epilepsy, this diagnosis being highest in the hierarchy).
We examined the number and proportions of newly initiated patients on each specific AED each year. A new user was defined as an individual with at least one AED prescription dispensed each observation year, without having the same substance dispensed during the preceding year. Thus, an individual could be either a patient who was AED-na€ ıve or one who had switched from another AED between years. Switchers were defined as cases switching from index AED to another AED. Prevalence was defined as the number of children dispensed one or more AEDs in a particular year divided by the total number of children in the Swedish population in the same year. Sexspecific cumulative incidence was defined as the number of children initiated on AEDs in a particular year divided by the number of children in the Swedish population in the same year. Both prevalence and incidence of use were expressed as rates per 1000 children, together with 95% confidence interval (CI).
Standard descriptive statistics were used, and data are presented as numbers or proportions. Statistical analyses were performed with Microsoft Excel 2016 (v16.0) and SAS EG 6.1 (SAS Institute Inc., Gary, NC, USA).
Sensitivity analyses. Sensitivity analyses of the time windows for identifying history of diagnoses were performed, comparing measurements at 1-, 6-, 24-and 60-month intervals prior to dispensing date.
Ethical considerations. The study was approved by the Regional Ethical Review Board in Stockholm, Sweden, Dnr 2015/660-31.
Results

Overall utilization of AEDs.
A total of 68,013 prescriptions of AEDs were dispensed to 22,262 children and adolescents (51% boys) aged 0-17 years between 2007 and 2014. The prevalence of AED use was slightly higher in boys than in girls each calendar year and increased with increasing age in both sexes from 2.22/1000 (95% CI 2.19-2.28) in preschoolers to 6.35/1000 (95% CI 6.32-6.37) in adolescents. The total number of dispensed prescriptions increased from 4.34/1000 (95% CI 4.29-4.39) in 2007 to 4.38/1000 (95% CI 4.32-4.43) in 2014. A total of 1727 patients were dispensed two or more AEDs at the same date during the study period.
In all, 18,131 first prescriptions of AEDs were dispensed during the study period (table 2). The mean age at time of initiation was 9.5 years. The total cumulative incidence of AEDs increased during the study period in boys from 1.08/1000 (95% CI 0.93-1.23) in 2007 to 1.15/1000 (95% CI 1.01-1.29) in 2014 and in girls from 1.16/1000 (95% CI 1.02-1.31) in 2007 to 1.21/1000 (95% CI 1.07-1.36) in 2014. In the age group 0-13 years, the cumulative incidence was on average 1.2 times higher in boys, and in the age group 14-17 years, the cumulative incidence was on average 1.6 times higher in girls.
Among patients initiated on therapy, the majority were dispensed monotherapy (98%). Valproic acid and lamotrigine were the most frequently used AEDs for initiation of therapy, independent of indication of use ( fig. 1) . When stratified by sex, valproic acid was most common in boys (38%), while lamotrigine was most common in girls (34%). The cumulative incidence increased in boys and girls throughout the study period.
A total of 2003 children and adolescents were dispensed only one single AED prescription during the study years (12% of the girls and 10% of the boys). Very few patients switched from another AED; in total, 1694 children and adolescents (9%) had claimed another AED within the previous 12 months.
Indications for antiepileptic prescribing. Approved diagnoses were recorded for 77% (13, 959) of the children and adolescents within 1 year prior to the first dispensation. The most common diagnosis was epilepsy, recorded for 49% of all boys and 44% of all girls. There were more girls having a diagnosis of a psychiatric or pain disorder, while more boys had a diagnosis of epilepsy or migraine (table 3). Figure 2 shows the impact of using time windows of different lengths when identifying diagnoses prior to the first AED prescription claim. The proportion of children with any of the indicated diagnoses increased to 80% when assessing diagnoses recorded within 2 years prior to initiation and to 82% when assessing diagnoses recorded within 5 years to initiation.
Utilization of AEDs in epilepsy.
The total utilization of AEDs for epilepsy increased slightly during the study period and accounted for 68% of the total utilization of AEDs in children in 2014. Boys were most likely to be initiated on valproic acid (31%), while girls were most likely to be initiated on lamotrigine (27%) (fig. 3A,B) . There was an increase in levetiracetam initiations throughout the study period with similar trends in both boys and girls. Over the same time period, carbamazepine initiations decreased while oxcarbazepine initiations increased. Rates of the remaining AEDs were largely unchanged. The newest AEDs (zonisamide, stiripentol, rufinamide, lacosamide, eslicarbazepine and perampanel) accounted for 0.3% of the total AED initiations in 2014 (Table S2) .
Among children younger than 2 years of age, phenobarbital was the most initiated in both boys and girls. In the age group 2-8 years, valproic acid was most commonly initiated in both sexes and increased to a similar extent. After the age of 9, initiations of valproic acid declined in girls and lamotrigine initiations increased.
For unspecified convulsions, the proportion initiated on AEDs remained stable for both boys and girls during the study period, with an average of 15% and 13%, respectively. Valproic acid was most frequently initiated in boys (26%), while phenobarbital was more common in girls (26%) ( Table S3) .
Utilization of AEDs in non-epilepsy disorders.
The total utilization of AEDs in children with non-epilepsy disorders diagnosis, that is neither epilepsy nor unspecified convulsions, decreased during the study years, from 33% of the total AED use in 2007 to 26% in 2014.
Psychiatry. The use of AEDs in psychiatry accounted for 5% of the total AED use in 2014 (6.7% of the girls and 3.2% of the boys). The number of new AED prescriptions in psychiatry increased from 193 in 2007 to 228 in 2014. Girls were most likely to be initiated on lamotrigine (77%), while boys were initiated on lamotrigine (55%) or valproic acid (27%) (fig. 4A,B) . During the study period, lamotrigine incidence increased while valproic acid initiations decreased in (48) 318 (14) 228 (10) 164 (7) 38 (1.1) 533 (20) 1873 (100) both boys and girls. A full list on AEDs used in psychiatry is provided in Table S4 .
Pain disorders and migraine. In pain disorders, the utilization of AEDs accounted for 2.4% of the total use in 2014 (2.8% of the girls and 2.1% of the boys). The number of initiations for pain disorders increased during the study period and to a larger extent in girls than in boys. In the beginning of the study period, lamotrigine was the most initiated AED in boys (27%) and gabapentin in girls (30%). At the end of the period, gabapentin was most common in both sexes (23% and 47%, respectively) (Table S5) . Migraine constituted less than 0.5% of the total AED use in 2014 in both boys and girls. The number of new AED prescriptions in migraine increased from 12 in 2007 to 38 in 2014. In total, more boys than girls had migraine (100 versus 86, respectively), and they were most frequently initiated on topiramate (52% of the boys and 58% of girls) (Table S6) .
Discussion
The present study presents the utilization of AEDs in Swedish children and adolescents. To our knowledge, this study is the first large-scale contribution to the knowledge of AED utilization patterns on different indications in children and adolescents in Sweden.
Overall, valproic acid and lamotrigine were the most commonly initiated AEDs in our cohort. There has been concern about the use of valproic acid in young children due to the risk of hepatotoxicity, a rare but potentially fatal adverse event [25] . The risk of adverse events from valproic acid has been shown to be higher in female than male users, particularly after puberty when the risk of weight gain and hair loss is increased in girls [26] . Furthermore, the well-known risk of teratogenic malformations and long-term intellectual effect on children with foetal exposure to valproic use during pregnancy [27, 28] have caused FDA and EMA to recommend that valproic acid is used with caution in girls and women who may become pregnant [29] , and on the diagnosis bipolar disease, the drug is banned in France [30] . This may be reasons for the lower use of valproic acid in girls compared with boys. This may also explain the higher use of lamotrigine, a drug with similar indications as valproic acid but with a more benign effect during pregnancy [31] . Our findings of sex differences in use of valproic acid in epilepsy compared to psychiatry reflect prescriber's knowledge about the foetal risks associated with these AEDs.
Epilepsy.
As expected, the use of AEDs in this cohort was mainly restricted to epilepsy. Similar findings have been reported in studies from UK (75% [18] ) and The Netherlands (80% [8] ). Valproic acid was the most used AED in epilepsy, not surprisingly as the substance is a first-line recommendation for generalized seizures in children in Sweden [32] . Carbamazepine is effective in many seizure types but may worsen others and is therefore not recommended as often as other AEDs in children [33] , which could explain the decreased use during the study period. The Medical Products Agency (MPA) recommends oxcarbazepine to children because of its 'high evidence in children' [32] . In meta-analysis, oxcarbazepine has been shown to be equally efficient as comparative AED with less impact on cognitive function [34, 35] . The increase in levetiracetam could be attributed to its generally better tolerability ANTIEPILEPTIC DRUGS AND DIFFERENT DIAGNOSES than conventional AEDs [36] . Levetiracetam was introduced to the worldwide market in 2000 and became available as a generic in Europe in 2011 [37] .
Psychiatry.
In this cohort, the proportion with a diagnosis of a psychiatric disorder was lower than seen in children and adolescents in The Netherlands (10% [8] ). This patient category, if not severe, is often managed in primary care in Sweden. Our findings that psychiatric diagnoses were more common in girls are reasonable as these are more common among females [3] . The efficacy of lamotrigine in bipolar disorder, in addition to valproic acid and carbamazepine, has been shown in adults [38] . Preliminary efficacy of lamotrigine has been shown in adolescents [39, 40] but is lacking in children. Lamotrigine and carbamazepine are not yet approved in Sweden for use in bipolar disorder. However, there is strong evidence that valproic acid is effective in the treatment of acute manic episodes and may even prevent recurrence of mania [41] . For that reason, EMA recommended all products containing valproic acid be approved for treatment of bipolar disorder/mania in 2010 [42] . In Sweden, valproic acid is recommended as an alternative to the second-line treatment lithium in acute mania in boys and is not recommended at all to girls [43] .
Pain disorders and migraine. We found that pain diagnoses were more common in girls. It is known that more females suffer from pain conditions [44] . Some experimental studies have found women to exhibit greater pain sensitivity than men, and sex differences in pain tolerance have been reported also in children and adolescents [44] . There is also some evidence suggesting sex differences in response to pain treatment [44] . Currently, there are no drugs that have been evaluated and approved for the treatment of neuropathic pain in children. These children are treated with the same type of drug as adults [45] . More boys were dispensed AEDs as migraine prophylaxis, which is reasonable as the migraine prevalence is higher in boys in the younger ages, while girls are more affected after puberty and in adulthood [7] . The proportion with migraine diagnoses was lower compared to what has been seen in children in The Netherlands (5%). One possible explanation could be poor recording of migraine diagnoses in Sweden [46] . As expected, topiramate was the most frequently used AED. Topiramate, and also valproic acid, has shown to be efficacious for preventing attacks in adults and is recommended as preventive treatment of migraine [47] . However, in children, topiramate has limited evidence supporting efficacy, while there is no evidence of efficacy for valproic acid [48] . Recently, topiramate was approved by the FDA for use in adolescents aged 12-17 years old [49] . In Sweden, the firstline treatment for migraine is propranolol, which is the only drug approved for this indication in children [45] .
Strengths and limitations.
The main strength of this study is the complete coverage of drug dispensing data. Consequently, analyses of prevalence and incidence of drug utilization are likely to provide good estimates of drug use. However, data on drug dispensing do not reflect what is prescribed or actually used even though it is considered a good proxy [50] . Although we had access to registered diagnoses, the actual indication on which AEDs were prescribed was not known. The Swedish Prescribed Drug Register does not include information about the underlying clinical diagnosis for prescription of drugs, and therefore, we estimated possible indications based on the approved indications of the AEDs. Consequently, there is uncertainty in the association between indication and prescriptions. A validation approach could be to analyse the free text in the patient's prescription, but as the diagnosis is not always specified and there was a large sample size, this was not feasible. A fifth of all children and adolescents initiated on AEDs had none of the approved diagnoses within 1 year from the first prescription. It was not possible to determine whether this could be explained by inadequate recording of diagnoses or off-label prescribing. However, we only studied diagnoses recorded within 5 years prior to the first AED dispensation, and it is possible that some had their diagnosis recorded earlier that was excluded. We examined only the first recorded utilization of an AED for each patient. It is possible that patients had used AEDs prior to the washout period for which we did not have any information. Using a washout period of 1 year is appropriate for identifying incident treatment with AED in patients with chronic diseases, such as epileptic disorders, which was the most common registered diagnose of the children in this study. However, the 1-year washout may not be appropriate for identifying incident treatment in pain disorders. A further potential limitation is that diagnoses may have been missed if recorded in primary care.
Conclusions
In conclusion, this nationwide cross-sectional study described the use of various AEDs in epilepsy and other disorders in children and adolescents in Sweden. AEDs were found to be most commonly used for epilepsy, accounting for approximately 70% of the total utilization following diagnosis. The initiations of AEDs increased during the study years and in both epilepsy and non-epilepsy disorders. In general, the prescribing of individual AEDs seems to be in accordance with the approved indications. However, there is some use in other disorders, especially pain disorders, where the use is off-label, which warrants further studies.
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